Skip to content
Research/Peptides/PT-141

PT-141

compound

preliminary evidencePublic

Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.

Category: Peptides·Updated 5/20/2026
OverviewScienceClinicalSafetyPapersProtocolsOutcomes

PT-141

Cyclic heptapeptide melanocortin receptor agonist. FDA-approved for HSDD in women (Vyleesi). Activates MC3R and MC4R in CNS to increase sexual arousal.

ScienceComing soon
ClinicalComing soon
SafetyComing soon
PapersComing soon
ProtocolsComing soon
OutcomesComing soon